Put companies on watchlist
Cannovum AG
ISIN: DE000A2LQU21
WKN: A2LQU2
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cannovum AG · ISIN: DE000A2LQU21 · EQS - Company News (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1513363
15 December 2022 09:00AM

Cannovum AG share enters Xetra trading


EQS-News: Cannovum AG / Key word(s): Miscellaneous/Research Update
Cannovum AG share enters Xetra trading

15.12.2022 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 15.12.2022 - The share of Cannovum AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has been included in trading on the Xetra and Frankfurt Stock Exchange. This means that Cannovum AG is now represented on Germany's largest and most important stock exchange.

 

"This is an important milestone on our way to becoming one of the market leaders in the upcoming legal cannabis segment," says Pia Marten, CEO and co-founder of Cannovum AG. "By listing on the most important German trading platform, we increase Cannovum AG's visibility in the capital markets and make it easier for investors to profit from cannabis legalization."

 

Even before the listing on the Xetra market, the first analysts reported on Cannovum AG's stock. From Sphene Capital, an independent research firm for small and mid caps, the share has received a Buy rating with a price target of 15.30 euros.

 

Contact:

Klaus Madzia, IR & PR, Cannovum AG

Phone +49 30 3982 163 62, klaus.madzia@cannovum.com

 

Cannovum AG is the first German fully licensed cannabis company listed on the stock exchange. The shares are traded on the stock exchanges in Frankfurt/Xetra, Düsseldorf, Munich, Berlin, Hamburg and gettex. Cannovum AG is ready for the legalization of cannabis and well-prepared: both for sales through pharmacies and through licensed specialty stores and online shipping.

 

Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer, and manufacturer of high-quality medical cannabis products based in Berlin. Already today, Cannovum AG is a market leader in the medical cannabis sector.

 

Currently the company works on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies.

 

For more information, visit https://cannovum.com/investor-relations

 

 



15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
Germany
Phone: +49 (0)30 3982 16360
E-mail: ir@cannovum.com
Internet: www.cannovum.com
ISIN: DE000A2LQU21
WKN: A2LQU2
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Hamburg, Munich
EQS News ID: 1513363

 
End of News EQS News Service

1513363  15.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1513363&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.